MYC and therapy resistance in cancer: risks and opportunities

G Donati, B Amati - Molecular oncology, 2022‏ - Wiley Online Library
The MYC transcription factor, encoded by the c‐MYC proto‐oncogene, is activated by
growth‐promoting signals, and is a key regulator of biosynthetic and metabolic pathways …

Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress

HS Budi, FN Ahmad, H Achmad, MJ Ansari… - Stem Cell Research & …, 2022‏ - Springer
Due to the overexpression or amplification of human epidermal growth factor receptor 2
(HER2) with poor prognosis in a myriad of human tumors, recent studies have focused on …

Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche

MA Lawson, MM McDonald, N Kovacic… - Nature …, 2015‏ - nature.com
Multiple myeloma is largely incurable, despite development of therapies that target myeloma
cell-intrinsic pathways. Disease relapse is thought to originate from dormant myeloma cells …

VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2

D Zhao, C Pan, J Sun, C Gilbert, K Drews-Elger… - Oncogene, 2015‏ - nature.com
Vascular endothelial growth factor-A (VEGF), a potent angiogenic factor, is also implicated in
self-renewal in several normal tissue types. VEGF has been shown to drive malignant stem …

Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer

R Thakur, R Trivedi, N Rastogi, M Singh, DP Mishra - Scientific reports, 2015‏ - nature.com
Cancer stem cells (CSCs) are responsible for aggressive tumor growth, metastasis and
therapy resistance. In this study, we evaluated the effects of Shikonin (Shk) on breast cancer …

MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis

BG Cuiffo, A Campagne, GW Bell, A Lembo, F Orso… - Cell stem cell, 2014‏ - cell.com
Mesenchymal stem/stromal cells (MSCs) are progenitor cells shown to participate in breast
tumor stroma formation and to promote metastasis. Despite expanding knowledge of their …

Breast cancer stem cell: the roles and therapeutic implications

F Yang, J Xu, L Tang, X Guan - Cellular and Molecular Life Sciences, 2017‏ - Springer
Breast cancers have been increasingly recognized as malignancies displaying frequent
inter-and intra-tumor heterogeneity. This heterogeneity is represented by diverse subtypes …

The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer

Y Pang, G Bai, J Zhao, X Wei, R Li, J Li, S Hu… - Journal of translational …, 2022‏ - Springer
Background Endometrial cancer (EC) is the most common gynecological malignancy in
developed countries. Efficacy of the bromodomain 4 (BRD4) inhibitor JQ1 has been reported …

Overcoming tamoxifen resistance of human breast cancer by targeted gene silencing using multifunctional pRNA nanoparticles

Y Zhang, M Leonard, Y Shu, Y Yang, D Shu, P Guo… - ACS …, 2017‏ - ACS Publications
Most breast cancers express estrogen receptor (ER) α, and the antiestrogen drug tamoxifen
has been widely used for their treatment. Unfortunately, up to half of all ERα-positive tumors …

Impact of c-MYC expression on proliferation, differentiation, and risk of neoplastic transformation of human mesenchymal stromal cells

S Melnik, N Werth, S Boeuf, EM Hahn… - Stem cell research & …, 2019‏ - Springer
Background Mesenchymal stromal cells isolated from bone marrow (MSC) represent an
attractive source of adult stem cells for regenerative medicine. However, thorough research …